icon

ACTC:  The year opened for Advanced Cell pretty much where 2010 left off - on a continued run from the nickel mark after the FDA approved the start of clinical trials for ACT's stem cell based treatment for severe blindness. 

Advance Cell became only the second company ever approved to commence su...

Read more

MHAN:  Manhattan Pharmaceuticals gave us a good synopsis on Monday of how penny stocks move quick when they move.  After a prolonged period of trading for just a couple of pennies, MHAN jumped to a high of eight cents after a press release hit the wires announcing a settlement with Nordic Biotech...

Read more

MHAN:  2011 is turning out to be quite a decent year already for shareholders and traders of Manhattan Pharmaceuticals.  Just two weeks after the resolution of a share dispute between Manhattan and its Hedrin joint venture partner surged shares to a quick quadruple in price, the company added news...

Read more

Mannkind: Denied Yet Again

Posted by Posted by VFC on Jan 20, 2011
Just a couple of days after highlighting MNKD as a 'Stock to Watch' for the coming weeks, the company announced that it had received a 'complete response' letter from the FDA announcing that more trials would be needed before the FDA would once again consider approving Afrezza, Mannkind's develo...

Read more

AMRN: Amarin Corp continues to fly higher as the company continues to produce positive headlines weeks after announcing positive Phase III MARINE results for AMR101, a treatment for high triglycerides.

Shortly after making that announcement, it became known that another ongoing Phase III trial for AM...

Read more

ACTC: The new year has maintained the recent volatility of Advanced Cell Technology, with shares bouncing all over the place betweent fourteen and twenty six cents over the past few trading days.


After ending 2010 on a high note after the FDA approved the commencement of ACT's trial for Stargardt's m...

Read more